Working in Respiratory Diseases – Our Capabilities
As this year’s ERS meeting is about to kick off, we’ve looked back at the last three years at TherapeutAix and the 20 projects we have supported in the respiratory space. Most of these projects have been in pulmonary fibrosis, but there were also projects targeting COPD and other pulmonary indications. Our work in the […]
Collaboration and Outsourcing in Drug Discovery – Presentation
Last month, we had the pleasure of hosting the “Collaboration and Outsourcing in Drug Discovery” Workshop at this year’s Bio2Business BOS Virtual event. The workshop provided an excellent opportunity to explain the TherapeutAix Approach, using science-led collaboration with our network of R&D partners to offer bespoke solutions to challenges. Included in the workshop were talks […]
TherapeutAix to host Outsourcing Workshop at BOS Virtual 2021
Darcey Black and Simon Cruwys will be running the Outsourcing Workshop at this year’s BOS Virtual. Biotech Outsourcing Strategies is an established outsourcing focused conference and exhibition for the international Pharmaceutical industry. The event scope is focused on Discovery outsourcing and CMC outsourcing for both small molecules and biologics (primarily development stage). Darcey will be introducing the session and will explain the TherapeutAix model for collaboration […]
NASH – Challenges for drug development
It’s International NASH Day – and it’s also a while since we have last discussed NASH on the blog. In fact, even more has changed from the time when our review on NASH was published in 2019 – all 4 Phase III programs that were ongoing at that time (for obeticholic acid, elafibranor, cenicriviroc, and […]
Pitfalls with Oral Drug Administration in IPF
In the first 3 parts of our blog series on targeted delivery in idiopathic pulmonary fibrosis (IPF), we focused on the potential of inhaled delivery and other targeting strategies to deliver efficacy uplifts for agents as an add-on to the standard of care, while minimising the likelihood of additive side effects. In this fourth installment, we highlight […]
First-in-Human Clinical Trials
The Challenge: TherapeutAix was contacted by an innovative biotech company that was undertaking final preparations for First-in-Human clinical trials. It was known that their biologic has a complex metabolic pathway in vivo. One of the bioanalytical methods needed a major overhaul to be on the same technical level as the rest of the analytical toolbox. […]
Asset for Fibrotic Disease
The Challenge: TherapeutAix was approached by a US-based biotech company to review an asset that they were considering repositioning for fibrotic disease. The company asked for specific help in reviewing existing data, defining the steps then required to take the asset to IND-enabling studies and into the clinic. The Action: The task was to review the […]
Target and Asset Review
The Challenge: TherapeutAix was approached by a small virtual biotech to review a target and asset that for a rare fibrotic disease. The company asked for specific help in reviewing the target, existing data, defining the steps then required to take the asset to IND and into the clinic. The task was to review the existing data and background information and to provide an […]
Translational Strategy
The Challenge: A small, highly virtualized biotech had identified an attractive target in fibrotic diseases and needed a translational strategy to generate clinical data that enables data-driven decision-making for future development as well as increases the asset value. The Action: TherapeutAix was contracted to define the translational approach scoping elements ranging from in vitro / in […]
Thoughts from the Extracellular Matrix Pharmacology Symposium
Last week the TherapeutAix team participated in the excellent Extracellular Matrix Pharmacology Symposium, hosted by our network partner Nordic Bioscience. This was a 2-day virtual event, with more than 500 scientists attending to share research and discuss all things extracellular matrix (ECM). Here on the blog, we are revisiting 3 points that got us thinking. Correlations with disease: Throughout the meeting, there was data demonstrating that differences in matrix […]